血清淀粉样蛋白P成分作为轻度认知障碍和阿尔茨海默病的生物标志物
Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease.
作者信息
Verwey Nicolaas A, Schuitemaker Alie, van der Flier Wiesje M, Mulder Sandra D, Mulder Cees, Hack C Erik, Scheltens Philip, Blankenstein Marinus A, Veerhuis Robert
机构信息
Department of Neurology, Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands.
出版信息
Dement Geriatr Cogn Disord. 2008;26(6):522-7. doi: 10.1159/000178756. Epub 2008 Dec 2.
BACKGROUND
Serum amyloid P component (SAP), present in amyloid-beta (Abeta) plaques in Alzheimer's disease (AD), may protect Abeta deposits against proteolysis, thereby promoting plaque formation. The aim was to investigate if SAP levels in cerebrospinal fluid (CSF) and serum can be used to discriminate controls, AD and mild cognitive impairment (MCI) patients, and to identify incipient AD among MCI patients.
METHODS
SAP levels in CSF and serum were determined in 30 controls, 67 MCI and 144 AD patients. At follow-up, 39 MCI patients had progressed to dementia, while 25 had remained stable (mean follow-up time: 2.6 +/- 1.0 and 2.1 +/- 0.8 years).
RESULTS
Cross-sectionally no differences were found in SAP levels in CSF and serum between the groups. MCI patients that had progressed to dementia at follow-up had lower CSF SAP levels (13 microgram/l, range 3.3-199.3 microgram/l) than MCI nonprogressors (20.2 microgram/l, range 7.0-127.7 microgram/l; p < 0.05) [corrected]. A low CSF SAP level was associated with a 2-fold increased risk of progression to AD (hazard ratio = 2.2; 95% confidence interval = 0.9-5.4).
CONCLUSION
Our data suggest that measurement of CSF SAP levels can aid in the identification of incipient AD among MCI patients.
背景
血清淀粉样蛋白P成分（SAP）存在于阿尔茨海默病（AD）的β淀粉样蛋白（Aβ）斑块中，可能保护Aβ沉积物免受蛋白水解，从而促进斑块形成。目的是研究脑脊液（CSF）和血清中的SAP水平是否可用于区分对照组、AD患者和轻度认知障碍（MCI）患者，并在MCI患者中识别早期AD。
方法
测定了30名对照组、67名MCI患者和144名AD患者脑脊液和血清中的SAP水平。随访时，39名MCI患者进展为痴呆，25名患者病情保持稳定（平均随访时间分别为2.6±1.0年和2.1±0.8年）。
结果
横断面分析显示，各组脑脊液和血清中的SAP水平无差异。随访时进展为痴呆的MCI患者脑脊液中的SAP水平（13微克/升，范围3.3-199.3微克/升）低于未进展的MCI患者（20.2微克/升，范围7.0-127.7微克/升；P<0.05）[校正后]。脑脊液中低SAP水平与进展为AD的风险增加2倍相关（风险比=2.2；95%置信区间=0.9-5.4）。
结论
我们的数据表明，测定脑脊液中的SAP水平有助于在MCI患者中识别早期AD。
Zotero 插件